271 related articles for article (PubMed ID: 15539465)
41. Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.
Berge G; Lauridsen C; Sando SB; Holder DJ; Møller I; Aasly JO; Bråthen G; Savage MJ; White LR
J Alzheimers Dis; 2016; 49(2):493-502. PubMed ID: 26484901
[TBL] [Abstract][Full Text] [Related]
42. Small cisterno-lumbar gradient of phosphorylated Tau protein in geriatric patients with suspected normal pressure hydrocephalus.
Djukic M; Spreer A; Lange P; Bunkowski S; Wiltfang J; Nau R
Fluids Barriers CNS; 2016 Aug; 13(1):15. PubMed ID: 27581842
[TBL] [Abstract][Full Text] [Related]
43. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.
Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M
J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972
[TBL] [Abstract][Full Text] [Related]
44. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.
Lelental N; Brandner S; Kofanova O; Blennow K; Zetterberg H; Andreasson U; Engelborghs S; Mroczko B; Gabryelewicz T; Teunissen C; Mollenhauer B; Parnetti L; Chiasserini D; Molinuevo JL; Perret-Liaudet A; Verbeek MM; Andreasen N; Brosseron F; Bahl JM; Herukka SK; Hausner L; Frölich L; Labonte A; Poirier J; Miller AM; Zilka N; Kovacech B; Urbani A; Suardi S; Oliveira C; Baldeiras I; Dubois B; Rot U; Lehmann S; Skinningsrud A; Betsou F; Wiltfang J; Gkatzima O; Winblad B; Buchfelder M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2016 Mar; 52(1):51-64. PubMed ID: 26967210
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.
Reijn TS; Rikkert MO; van Geel WJ; de Jong D; Verbeek MM
Clin Chem; 2007 May; 53(5):859-65. PubMed ID: 17395712
[TBL] [Abstract][Full Text] [Related]
47. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
49. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid.
Obeid R; Kasoha M; Knapp JP; Kostopoulos P; Becker G; Fassbender K; Herrmann W
Clin Chem; 2007 Jun; 53(6):1129-36. PubMed ID: 17384003
[TBL] [Abstract][Full Text] [Related]
50. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
51. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
52. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
Olsson A; Vanderstichele H; Andreasen N; De Meyer G; Wallin A; Holmberg B; Rosengren L; Vanmechelen E; Blennow K
Clin Chem; 2005 Feb; 51(2):336-45. PubMed ID: 15563479
[TBL] [Abstract][Full Text] [Related]
53. Clinical evaluation of the levels of 12 cytokines in serum/plasma under various storage conditions using evidence biochip arrays.
Guo GH; Dong J; Yuan XH; Dong ZN; Tian YP
Mol Med Rep; 2013 Mar; 7(3):775-80. PubMed ID: 23291902
[TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
56. Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.
Herukka SK; Rummukainen J; Ihalainen J; von Und Zu Fraunberg M; Koivisto AM; Nerg O; Puli LK; Seppälä TT; Zetterberg H; Pyykkö OT; Helisalmi S; Tanila H; Alafuzoff I; Hiltunen M; Rinne J; Soininen H; Jääskeläinen JE; Leinonen V
J Alzheimers Dis; 2015; 46(1):261-9. PubMed ID: 25720406
[TBL] [Abstract][Full Text] [Related]
57. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
58. CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis.
Pietroboni AM; Schiano di Cola F; Scarioni M; Fenoglio C; Spanò B; Arighi A; Cioffi SM; Oldoni E; De Riz MA; Basilico P; Calvi A; Fumagalli GG; Triulzi F; Galimberti D; Bozzali M; Scarpini E
Mult Scler; 2017 Jul; 23(8):1085-1091. PubMed ID: 27754941
[TBL] [Abstract][Full Text] [Related]
59. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
[TBL] [Abstract][Full Text] [Related]
60. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
